News

: NEWS INDEX

 

• BioTech Forum Science Conference - Register now / NB! Poster deadline: 27 August
• Medicon Valley Drug Development Network Meeting
• BioInvent and Cartela reach the first milestone in drug development for osteoarthritus treatment
• Highlight on research in Denmark in the 30 September 2004 issue of Nature
• Exiqon enters into worldwide licencing agreement with U.S. Genomics
• Evolva Biotech raises EUR 12 millon from first round of funding
• MIP Technologies launches new separation product
• Sweden is the world's top country for biotech research
• Nanosep - innovative newcomer in Medicon Valley

 

: MVA NEWS

 

BioTech Forum Science Conference - Register now / NB! Poster deadline: 27 August

5-7 October 2004 / Bella Center / Copenhagen

 

 

MVA invites participants to submit abstracts of their ongoing research for poster presentation at BioTech Forum Science Conference 2004. The chairmen of the sessions will select qualified and relevant abstracts for poster presentations. All posters will participate in selection for the Medicon Valley Poster Award.
More information... (in English) www.mva.org/composite-946.htm

Register by clicking here

 

Medicon Valley Drug Development Network Meeting

8 September 2004 / Øresundshuset / Copenhagen

This afternoon workshop will discuss the formulation of drug trial products as well as an overview of regional service and technology providers in the field of formulations and drug delivery.

More information... (in English) www.mva.org/composite-1021.htm

 

 

: MEDICON VALLEY NEWS

 

BioInvent and Cartela reach the first milestone in drug development for osteoarthritus treatment

The two Swedish companies, both based in Lund, have reached the first milestone in their research collaboration to develop an antibody based drug to treat osteoarthritus.

More information... (in English) www.mva.org/composite-1098.htm

 

Exiqon enters into worldwide licencing agreement with U.S. Genomics

U.S. Genomics and Exiqon have entered into a worldwide license agreement to incorporate Exiqon’s A-Quencher into reagent kits for the U.S. Genomics Trilogy™ platform.

More information... (in English) www.mva.org/composite-1099.htm

 

Evolva Biotech raises EUR 12 millon from first round of funding

The Danish biotech company Evolva recently announced that it has raised EUR 12 million of equity financing in a first-closing of its A-round. The financing was led by Aravis and included new investors Novartis Venture Fund, Yamanouchi Venture Capital and Dansk Innovationsinvestering. Existing investors Symbion Capital and Vaekstfonden also participated.

More information... (in English) www.mva.org/composite-1100.htm

 

Highlight on research in Denmark in the 30 September 2004 issue of Nature

Nature's Highlight on Denmark will be introduced with an article from the Danish Ministry of Science, Technology and Innovation outlining the current situation of research in Denmark and will be distributed at the BioTech Forum in Bella Center, 5-7 October 2004 in Copenhagen.

More information... (in English) www.mva.org/composite-1101.htm

 

MIP Technologies launches new separation product of benefit to the pharmaceutical, veterinary, food and environmental industries

MIP Technologies AB has launched a new product for the Separations market, to extend the company's range of innovative products. The company is dedicated to the commercialization of innovative, molecular imprinting technology-based products, directly and through collaborations. MIP Technologies is headquartered in Lund, Sweden.

More information... (in English) www.mva.org/composite-1102.htm

 

Sweden is the world's top country for biotech research and has a culture of innovation that breeds start-up companies, according to Newsweek

The 26 July issue of the US news magazine carries an analysis of Sweden's biotech industry that strongly praises the country for the extent of its commitment to research and development. The article cites a Cap Gemini Ernst & Young report, published in March 2004, stating that Sweden offers the best climate for biotech research and innovation in Europe, as well as the highest quality work force.

More information... (in English) www.mva.org/composite-1103.htm

 

Nanosep - innovative newcomer in Medicon Valley

Nanosep AB develops technology for separating and purifying proteins, peptides and smaller molecules for further structure determination. The company has developed a new technique, based on nanotechnology which requires less material and is cleaner than traditional methods.
More information... (in English) www.mva.org/composite-1104.htm

 

 

: EVENTS

 

3rd ScanBalt Forum - The Competence Region

25-26 August 2004 / Turku / Finland
The 3rd ScanBalt Forum will create the future of the ScanBalt Competence region by establishing Scientific Platforms and Public-Private Partnerships. The aim of the forum is to promote networking, to create new contacts and collaboration for mutual benefit and funding of activities within biotechnology in the ScanBalt Competence Region.

More information... (in English) www.mva.org/composite-1070.htm

 

XVth International Workshop on Genetic Systems in the Rat

9-12 September 2004 / Copenhagen / Denmark

This series of workshops encourages scientific exchange and networking in rat research including: genomics, bioinformatics, (incl.